Authi K S, Evenden B J, Crawford N
Biochem J. 1986 Feb 1;233(3):707-18. doi: 10.1042/bj2330707.
In an earlier study we reported the effect of inositol 1,4,5-trisphosphate [Ins(1,4,5)P3] in releasing Ca2+ from highly purified human platelet intracellular membrane vesicles. [Authi & Crawford (1985) Biochem. J. 230, 247-253]. We have now investigated the metabolic and functional consequences of introducing Ins(1,4,5)P3 into saponin-permeabilized platelets. Washed human platelets when resuspended in a suitable medium were permeabilized with saponin (10-14 micrograms/ml) to allow entry of low-Mr water-soluble molecules without significant release of the cytoplasmic marker enzyme protein lactate dehydrogenase. Saponin-permeabilized platelets show identical platelet responses (shape change, aggregation and release of 5-hydroxy[14C]tryptamine) to both collagen (5 micrograms/ml) and thrombin (0.1 unit/ml) as obtained with intact cells, indicating that there is minimal disturbance to the surface membrane receptor topography for these two agonists. Ins(1,4,5)P3 (1-10 microM) added to saponin-treated platelets (but not to intact platelets) induced dose-related shape change, aggregation and release of 5-hydroxy[14C]tryptamine which at maximal doses was comparable with responses obtained with thrombin or collagen. The cyclo-oxygenase inhibitors indomethacin and aspirin, if added prior to saponization and Ins(1,4,5)P3 addition, completely inhibited both aggregation and release of 5-hydroxy[14C]tryptamine (EC50 for indomethacin, 50 nM; for aspirin, 30 microM). We believe that Ins(1,4,5)P3 induces the release of Ca2+ from intracellular storages sites which stimulates the Ca2+-dependent phospholipase A2 releasing arachidonic acid from membrane phospholipids. Arachidonic acid is then converted to the aggregatory prostanoids (prostaglandin H2 and thromboxane A2) resulting in the observed responses. This concept is supported by the use of the thromboxane receptor antagonists EPO 45 and EPO 92, both of which also completely inhibit Ins(1,4,5)P3-induced responses in saponin-permeabilized platelets. Electron microscopy of the platelet preparations revealed that thrombin- and collagen-induced platelet aggregates of intact and saponized cells were identical, showing extensive pseudopod formation and dense granule release. The Ins(1,4,5)P3-induced aggregates also showed similar dense granule release but an almost total absence of pseudopod formation. These results are discussed in the light of the second messenger role of Ins(1,4,5)P3 in stimulus-response coupling in platelets.
在一项早期研究中,我们报道了肌醇1,4,5 - 三磷酸[Ins(1,4,5)P3]从高度纯化的人血小板细胞内膜囊泡中释放Ca2+的作用。[Authi & Crawford(1985)《生物化学杂志》230, 247 - 253]。我们现在研究了将Ins(1,4,5)P3引入皂素通透化血小板后的代谢和功能后果。洗涤后的人血小板重悬于合适的培养基中,用皂素(10 - 14微克/毫升)通透化,以使低分子量水溶性分子进入,而细胞质标记酶蛋白乳酸脱氢酶无明显释放。皂素通透化的血小板对胶原蛋白(5微克/毫升)和凝血酶(0.1单位/毫升)的反应(形状改变、聚集和5 - 羟[14C]色胺释放)与完整细胞相同,表明这两种激动剂的表面膜受体拓扑结构受到的干扰最小。添加到皂素处理的血小板(而非完整血小板)中的Ins(1,4,5)P3(1 - 10微摩尔)诱导剂量相关的形状改变、聚集和5 - 羟[14C]色胺释放,最大剂量时与凝血酶或胶原蛋白诱导的反应相当。环氧化酶抑制剂吲哚美辛和阿司匹林,如果在皂化和添加Ins(1,4,5)P3之前添加,则完全抑制5 - 羟[14C]色胺的聚集和释放(吲哚美辛的EC50为50纳摩尔;阿司匹林为30微摩尔)。我们认为Ins(1,4,5)P3诱导Ca2+从细胞内储存部位释放,刺激Ca2+依赖性磷脂酶A2从膜磷脂中释放花生四烯酸。然后花生四烯酸转化为聚集性前列腺素(前列腺素H2和血栓素A2),导致观察到的反应。血栓素受体拮抗剂EPO 45和EPO 92的使用支持了这一概念,它们都完全抑制皂素通透化血小板中Ins(1,4,5)P3诱导的反应。血小板制剂的电子显微镜检查显示,完整细胞和皂化细胞中凝血酶和胶原蛋白诱导的血小板聚集体相同,表现为广泛的伪足形成和致密颗粒释放。Ins(1,4,5)P3诱导的聚集体也显示出类似的致密颗粒释放,但几乎完全没有伪足形成。根据Ins(1,4,5)P3在血小板刺激 - 反应偶联中的第二信使作用对这些结果进行了讨论。